Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Benzinga Newsdesk www.benzinga.com Positive 38.1%

Neg 0% Neu 0% Pos 38.1%

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.